FREMONT,
Calif., June 27, 2024 /PRNewswire/ -- Alamar
Biosciences, a company powering precision proteomics to enable the
earliest detection of disease in collaboration with the Biomarkers
of Aging Consortium, a consortium dedicated to the development and
validation of biomarkers of aging and longevity, announced today
the launch of the next phase of the Biomarkers of Aging Challenge
Series. This initiative aims to address one of the most significant
challenges in the longevity field: the need for reliable biomarkers
of biological age.
"The Challenge Series aims to drive innovation in the aging
biomarkers space and bring new scientists into this research
arena," said Dr. Jesse Poganik of
the Biomarkers of Aging Consortium. "Our hope is that challenge
participants leveraging the latest omics profiling methods and
novel modeling approaches will produce the next generation of aging
biomarkers."
The Biomarkers of Aging Challenge is supported by a unique,
high-quality dataset specifically generated for this initiative.
This dataset includes proteomic profiles using the NULISAseq™
Inflammation 250 and CNS Disease 120 Panels, DNA methylation
profiles, and aging outcome data from over 500 diverse
individuals. Importantly, it includes longitudinal follow-up
data, enabling the modeling of mortality risk, future disease
incidence, and multi-morbidity occurrence.
"The partnership between Alamar Biosciences and the Biomarkers
of Aging Consortium underscores a shared commitment to driving
innovation and collaboration in the field of aging biomarkers,"
said Dr. Yuling Luo, Founder,
Chairman & CEO of Alamar. "By leveraging Alamar's
high-sensitivity proteomics technologies and the Consortium's
extensive expertise and resources, the Challenge seeks to
accelerate progress in this critical area."
Submissions to the Challenge will not only contribute to
identifying current predictive biomarkers but also support
continuous technology development, paving the way for future
cost-effective technological advancements for longitudinal and
large-scale studies.
Challenge Timeline:
- March 1, 2024: Phase I -
Chronological Age Prediction Challenge begins
- July 1, 2024: Phase II -
Longevity Prediction Challenge (Mortality) begins
- November 1, 2024: Winners
celebration at the 2024 Biomarkers of Aging Conference in
Boston, MA
- Q1 2025: Phase III - Healthspan Prediction (Multi-morbidity)
begins
For more information about the Biomarkers of Aging Challenge
Series, please visit https://www.agingconsortium.org/challenge
About Alamar Biosciences, Inc.
Alamar Biosciences is a privately held life sciences company
with a mission to power precision proteomics to enable the earliest
detection of disease. The company's proprietary NULISA Platform
along with the ARGO™ HT System work seamlessly with the latest
advances in genomics to achieve single digit attomolar detection
sensitivity, greatly surpassing the most sensitive protein
detection technology on the market today. For more information,
please visit alamarbio.com.
About the Biomarkers of Aging Consortium
Founded in 2022, the Biomarkers of Aging Consortium is a group
of scholars and practitioners developing, validating, and
implementing biomarkers of aging and longevity. Our academic
members are affiliated with the leading research institutes and
groups in the field of aging. Our practitioners are at the
forefront of research and development in the longevity industry.
www.agingconsortium.org
View original content to download
multimedia:https://www.prnewswire.com/news-releases/alamar-biosciences-and-biomarkers-of-aging-consortium-join-forces-to-revolutionize-longevity-research-302184545.html
SOURCE Alamar Biosciences, Inc.